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The fetal liver is a major hematopoietic site containing progenitor
cells that give rise to nearly all blood cells, including B-1 cells.
Because the fetal liver is not a de novo site of hematopoietic stem
cell (HSC) or progenitor-cell emergence, it must be seeded by yolk
sac (YS)-derived erythromyeloid progenitors at embryonic day (E)
8.5–E10 and aorta-gonado-mesonephros (AGM)-derived HSCs at
E10.5–E11.5. Although the B-1 progenitor cell pool in the fetal liver
is considered to be of HSC origin, we have previously proposed
that YS-derived B-1 progenitors may also contribute to this pool.
Until now, it has been impossible to determine whether HSC-
independent B-1 progenitor cells exist in the fetal liver. Here, we
demonstrate the presence of transplantable fetal-liver B-1 and
marginal zone B progenitor cells in genetically engineered HSC-
deficient embryos. HSC-deficient YS and AGM tissues produce B-1
progenitors in vitro and thus may serve as sites of origin for the B-1
progenitors that seed the fetal liver. Furthermore, we have found
that core-binding factor beta (Cbfβ) expression is required for fe-
tal-liver B-1 progenitor cell maturation and expansion. Our data
provide, to our knowledge, the first evidence for the presence of
B-1 progenitor cells in the fetal liver that arise independently of
HSCs and implicate Cbfβ as a critical molecule in the development
of this lineage.
TEK | hemogenic endothelial cell | immune layered model
The immune layered model proposed by Herzenberg andHerzenberg in 1989 (1) predicted B-1 and B-2 lineage pro-
duction through three waves of B lymphopoiesis arising from
different precursors during development (2): According to this
model, the first wave gives rise exclusively to innate immune B
cells in early embryonic life and may be derived from progenitor
cells independent of hematopoietic stem cells (HSCs), chal-
lenging the stem-cell theory that all blood cells are products of
HSCs. The second and third waves are comprised of HSCs and
HSC-derived progenitors in the fetal liver, neonatal bone mar-
row (BM) (the second wave), and adult BM (the third wave),
respectively. Importantly, AA4.1+CD19+B220lo-neg B-1 specific
progenitors have been identified in the second wave (3). The
second wave produces more B-1 cells than B-2 cells whereas the
third wave displays an opposite skewing of B-cell differentiation
(4–7). In fact, the B-1 cell-producing abilities of HSCs and
common lymphoid progenitor cells decline with advancing age
(6), and, in particular, CD5+B-1a cells are not produced by adult
HSCs when examined by single HSC transplantation assay (7).
Although the second and third waves have been examined in
detail, it is unclear whether the first wave exists and contributes
to innate immunity in postnatal life and whether the B-1 pro-
genitor cells in wave 2 in the fetal liver are all HSC-derived or
contain derivatives of the wave 1 HSC-independent embryonic
progenitor cells.
Murine B-1 cells are innate immune cells (distinguished
from conventional B-2 cells by specific surface markers such as
IgMhiIgDloCD11b+), residing in the peritoneal and pleural cavities.
These cells produce stereotypic natural antibodies in a T cell-
independent manner and execute important roles in the first line
of defense against microbial infection (8, 9). B-1 cells are segre-
gated into CD5+B-1a and CD5−B-1b cells. Marginal zone (MZ)
B cells, named after the restricted localization of these cells in the
splenic marginal zone, are usually categorized as BM HSC-
derived B-2 cells but share similar functions with B-1 cells, such as
rapid production of IgM antibodies against bacterial pathogens in
a T cell-independent manner. There is evidence that a portion of
MZ B cells is also of embryonic or fetal origin (10–12).
We have recently reported that yolk sac (YS) and para-aortic-
splanchnopleura (P-Sp) hemogenic endothelial cells (HECs)
harvested before the first emergence of HSC give rise to trans-
plantable, functional B-1a, B-1b, and MZ B cells in vitro and thus
have provided supportive evidence for the first wave of B cells
(13). However, because we isolated and cultured YS/P-Sp cells in
vitro to allow them to differentiate into B-1 progenitor cells,
whether YS/P-Sp–derived B progenitor cells seed the fetal liver in
vivo and contribute to the B-1 progenitor cell pool or mature B-1
orMZB cells in postnatal life has never been established. In other
words, to address the question whether the first wave of B lym-
phopoiesis is present in vivo or not, we have to confirm the exis-
tence of HSC-independent B-1 progenitor cells in the fetal liver.
The fetal liver is an organ dependent upon hematopoietic
stem/progenitor cell seeding from different hematopoietic tissues.
Significance
All lymphoid cells are considered to be products of hemato-
poietic stem cells (HSCs); however, it has been suggested, but
not proven, that innate immune B-1 progenitor cells develop
independently of HSCs in the fetal liver. B-1 cells, especially
B-1a cells, are not replaced by adult bone marrow trans-
plantation. Thus, it is critical to understand the origin and
mechanisms required to sustain these cells in vivo because B-1
cells play important roles in the first line of defense against
microbial infection and in preventing organ damage in auto-
immune patients and infections in some patients after bone-
marrow transplantation. We demonstrate that B-1 progenitor
cells can develop independently of HSCs in the fetal liver and
that their development relies critically on the expression of
core-binding factor beta.
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It is an established concept that erythro-myeloid progenitors
(EMPs) derived from embryonic day (E) 8.5–E10 YSs seed the
fetal liver to support homeostatic hematopoiesis in the embryo
whereas HSCs that emerge in the aorta-gonado-mesonephros
(AGM) region seed the fetal liver at E11 and provide hemato-
poietic support later in development (14, 15). However, it is un-
known whether the YS/P-Sp HEC-derived B-1 lymphoid
progenitors seed the fetal liver. Because the B-1 progenitor cell
pool in the fetal liver is considered to be an HSC derivative and
because HSCs exist in the fetal liver concomitant with B-1 pro-
genitor cells, it has been impossible to prove the existence of
HSC-independent B lymphopoiesis in the fetal liver. To specif-
ically address this question, we have used a unique mouse model
devoid of HSC but known to possess some uncharacterized fetal-
liver B cells (16, 17).
Core-binding factor beta (CBFβ) is the common non–DNA-
binding subunit of the Cbf family of heterodimeric transcription
factors. By associating with CBFα subunits, CBFβ increases the
affinity of CBFα DNA-binding. Runt related transcription factor
1 (Runx1) also called core-binding factor alpha 2 (Cbfα2)−/− em-
bryos die at E12 and display severe deficiencies in definitive EMP,
lymphoid cells, and HSCs (18). CBFβ is required for Runx1 func-
tion, and loss of CBFβ in embryos leads to embryonic lethality
at E11–E13 similar to Runx1−/− embryos with a severe defect
in definitive hematopoiesis and HSCs (17, 19). However, when
Cbfβ expression was restored inCbfβ−/− embryos under transgenic
control of the endothelial promoter endothelial-specific receptor
tyrosine kinase (Tek) (Cbfβ−/−:Tek-GFP/Cbfβ), EMP formation
and rare B and T cells were observed (16). In these rescued em-
bryos, lymphoid progenitors (Lin−c-Kit+Flt3+) were detectable in
the E14 fetal liver and produced B or T cells in OP9 or OP9-DL1
in vitro cocultures, respectively. However, E14 Cbfβ−/−:Tek-GFP/
Cbfβ fetal-liver cells failed to reconstitute recipient peripheral
blood (PB) and BMupon transplantation, indicating thatCbfβ−/−:
Tek-GFP/Cbfβ embryos contain lymphoid progenitors without
transplantable HSCs. It has been previously reported that
lymphoid progenitor cells are present in the YS and P-Sp be-
fore HSC emergence at an early stage (E8.25–E9.5) of embryo
development (13, 20–23). Furthermore, the presence of multi-
potent progenitor cells with myeloid, B-cell, and T-cell lineage
potentials without long-term HSC activity also has been reported
(24–26). Whether the B and T progenitor cells emerge from
a commonHECor are independently generated has not been fully
resolved. Nonetheless, the fact that lymphoid progenitor cells are
present prior to HSC emergence suggests that the initial phases of
developmental hematopoiesis may not follow the same paradigm
as adult BM HSC development where all of the lymphoid pro-
genitor cells are HSC-derived (15, 27). Indeed, transplantable
HSCs were rescued when Cbfβ was expressed under transgenic
control of the Ly6a promoter in the Cbfβ−/− embryos (Cbfβ−/−:
Ly6a-GFP/Cbfβ), suggesting that Cbfβ is required in the Ly6a+
HECs for producing transplantable HSCs that repopulate mye-
loid and lymphoid lineages (16). Based on these findings and our
previous reports that B-1 (but not B-2) and T lymphoid progenitor
cells are present in the embryo beforeHSC emergence (13, 20), we
hypothesized that the unspecified B cells detected in the Cbfβ−/−:
Tek-GFP/Cbfβ embryos that do not harbor transplantable HSCs
are HSC-independent B-1 progenitor cells that constitute the first
wave of B lymphopoiesis.
In the present study, we confirm the existence of fetal-liver
AA4.1+CD19+B220− B-1 progenitor cells in the absence of
transplantable HSCs in vivo. YS and AGM cells from Cbfβ−/−:
Tek-GFP/Cbfβ embryos produce B-1 progenitor cells in vitro.
Our results clearly demonstrate the presence of B-1 and MZ B
progenitor cells in the fetal liver independent of HSCs and
suggest that these progenitor cells are likely to be derived in part
from YS/P-Sp sites. However, these B-1 progenitor cells do not
display persistent expression of GFP/Cbfβ because TEK is not
expressed once HECs become hematopoietic cells. Therefore,
this Cbfβ deficiency in B-1 progenitor population results in im-
paired maturation and expansion of these cells. Consistently, we
show that overexpression of Cbfβ in Cbfβ−/−:Tek-GFP/Cbfβ fetal-
liver cells via a retrovirus promotes engraftment of B-1 and MZ
B cells in recipient immunodeficient mice. Thus, our findings
demonstrate that persistent Cbfβ expression is required for the
maturation and expansion of B-1 progenitor cells during in vivo
development.
Results
B-1 Progenitor Cells Exist in the Fetal Liver in the Absence of HSCs.
First, we examined whether AA4.1+CD19+B220lo-neg B-1 pro-
genitor cells exist in the fetal liver of Cbfβ−/−:Tek-GFP/Cbfβ
embryos. As previously reported (16), Cbfβ−/−:Tek-GFP/Cbfβ
embryos can survive until birth in the absence of HSCs. The fetal
livers of Cbfβ−/−:Tek-GFP/Cbfβ embryos at E15.5 and E17.5
were of similar size to the fetal liver of wild-type (WT) littermate
embryos. Total fetal-liver mononuclear cell (MNC) counts from
E17.5 Cbfβ−/−:Tek-GFP/Cbfβ embryos were significantly lower
than WT embryos (Fig. 1B). As shown in Fig. 1A, lin−AA4.1+
CD19+B220lo-neg B-1 progenitor cells were detected in the fetal
livers of Cbfβ−/−:Tek-GFP/Cbfβ embryos from E15.5 until birth
although the frequency and total number were significantly lower
than WT values (Fig. 1 A–D and M). Furthermore, lin−AA4.1+
CD19+B220lo-neg B-1 progenitor cells were also detected in the
fetal spleen from E15.5 until birth (Fig. 1 G–J and N). Few
AA4.1+CD19+B220+ B cells were detected in the fetal liver
and spleen of Cbfβ−/−:Tek-GFP/Cbfβ embryos whereas WT fetal
liver contained more AA4.1+CD19+B220+ B cells than B-1
progenitor cells (Fig. 1 A, E–G, K, and L). AA4.1+CD19+B220+
cells are overlapping with AA4.1+B220+CD43+ proB cells (5).
Whereas adult BM AA4.1+CD19+B220+ cells give rise pre-
dominantly to B-2 cells, fetal-liver AA4.1+CD19+B220+ or
AA4.1+B220+CD43+ cells are known to give rise mainly to B-1
cells upon transplantation (3, 5). Thus, the fetal-liver AA4.1+
CD19+B220+ population contains more B-1 lineage than B-2
lineage cells and is considered to be differentiated from both
HSCs (through AA4.1+CD19−B220+ phenotype) and B-1 pro-
genitor cells as we have previously reported (13). Therefore,
severe reduction of AA4.1+CD19+B220+ cells in the fetal liver
(Fig. 1 E and F) and spleen (Fig. 1 K and L) is due to HSC
deficiency and an impaired maturation of HSC-independent B-1
progenitor cells in the Cbfβ−/−:Tek-GFP/Cbfβ embryos. Never-
theless, it is of note that Cbfβ−/−:Tek-GFP/Cbfβ fetal spleen
contains B progenitor cells (2.0 × 104 ± 1.7 × 104 cells) at 44% of
the number measured in WT fetal spleen (4.7 × 104 ± 1.3 × 104
cells) (by calculating total B progenitor cells in E17.5 spleen)
(Fig. 1N). This result suggests that at least 40% of B-1 progenitor
cells in the fetal-neonatal spleen are HSC-independent, a point
that contrasts with the common perception that all lymphoid
cells are HSC-derived.
B-1 Progenitors in Cbfβ−/−:Tek-GFP/Cbfβ Fetal Liver Fail to Mature
and Expand in Vitro. Although we have confirmed for the first
time, to our knowledge, that B-1 progenitors are present in the
HSC-deficient fetal liver, we have also observed a possible
maturation defect of B-1 progenitor cells in Cbfβ−/−:Tek-GFP/
Cbfβ embryos (Fig. 1). To examine the maturation capacity of
B-1 progenitor cells in Cbfβ−/−:Tek-GFP/Cbfβ fetal liver, AA4.1+
CD19+B220lo-neg B-1 progenitor cells from WT and Cbfβ−/−:
Tek-GFP/Cbfβ fetal liver were plated on OP9 stromal cells with
added IL-7 and Flt3-ligand. WT AA4.1+CD19+B220lo-neg cells
proliferated, forming cobblestones beneath the stromal cells, and
produced more than 106 nonadherent cells with CD19+B220+
(including IgM+) B cells in 7–10 d (Fig. 2A, Upper). In contrast,
Cbfβ−/−:Tek-GFP/Cbfβ AA4.1+CD19+B220lo-neg cells did not
proliferate as robustly although they produced cobble stones by
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17 d with 106 nonadherent cells, including a few CD19+B220+
cells and many Mac1+macrophages (Fig. 2A, Lower). Considering
the fact that AA4.1+CD19+B220lo-neg cells were originally
reported as B cell-macrophage bipotent progenitors (28), these
results indicated that loss of Cbfβ may have contributed to the
reduction of B lymphoid potential in this population. This is
compatible with a previous report that the B lymphoid potential
of lymphoid progenitor cells in Cbfβ−/−:Tek-GFP/Cbfβ embryos
was 30-fold less than in WT embryos (16). Thus, proliferation
and B-1 cell differentiation capacity were significantly impaired
in Cbfβ−/−:Tek-GFP/Cbfβ B-1 progenitor cells at least under the
coculture conditions we used in vitro.
YS and AGM Can Produce B-1 Progenitor Cells in the Embryo Devoid
of HSCs. The fetal liver is not a de novo site of hematopoietic cell
emergence and must be seeded by various hematopoietic pro-
genitor/stem cells derived from other hematopoietic tissues (15).
Because HSCs are not produced in Cbfβ−/−:Tek-GFP/Cbfβ em-
bryos, we examined the possible source of B-1 progenitor cells
that seed the fetal liver. We cocultured YS and P-Sp/AGM cells
with OP9 stromal cells as previously reported (13). As expected,
Cbfβ−/−:Tek-GFP/Cbfβ YS and AGM cells produced AA4.1+
CD19+B220+ B cells but at a lower frequency compared with
WT YS/AGM (Fig. 2B). These cultured YS/P-Sp/AGM-derived
AA4.1+CD19+B220+ B progenitor cells were confirmed to be-
come mature B-1 cells in vivo upon transplantation as previously
reported (13). Although there is a study suggesting that placenta
has the potential of producing B cells at a pre-HSC stage (29),
we found maternal B cells in the placenta at this time point
whereas YS and P-Sp derived B-1 cells were confirmed to be
embryonic in origin (13). Thus, although we cannot exclude the
possibility of the placenta as a production site for the first wave
of B-1 progenitor cells in Cbfβ−/−:Tek-GFP/Cbfβ embryos, our
data indicate that YS and AGM produce B-1 progenitor cells
that may seed the fetal liver in the Cbfβ−/−:Tek-GFP/Cbfβ em-
bryos devoid of HSCs.
B-1 Progenitor Cells Can Mature into B-1 and MZ B Cells in Vivo but at
Low Efficiency. Lin−AA4.1+CD19+B220lo-neg B-1 progenitor cells
were maintained until birth in Cbfβ−/−:Tek-GFP/Cbfβ mice
(B progenitor cells were present at 40% of the number of WT
mice in the spleen) (Fig. 1N), and mice died 1 d after birth as
previously reported (16). Because mature B-1 cells are not de-
tectable in the peritoneal cavity until 5 d after birth (30), we were
unable to find mature peritoneal B-1 cells in the Cbfβ−/−:Tek-GFP/
Cbfβ live-born neonates. To examine whether the B-1 progenitor
cells found in the fetal liver of Cbfβ−/−:Tek-GFP/Cbfβ embryos can
mature into B-1 cells in vivo, we transplanted fetal-liver MNCs
Fig. 1. B-1 progenitor cells exist in the Cbfβ−/−:Tek-
GFP/Cbfβ fetal liver (FL) and spleen. AA4.1+CD19+
B220lo-neg B-1 progenitor phenotype was examined
in the WT and Cbfβ−/−:Tek-GFP/Cbfβ fetal-liver and
spleen cells at each day from E15.5 until birth
(E18.5). The representative data for E15.5 and E17.5
are depicted. Lin−AA4.1+ gated FACS dot plots at
E15.5 and E17.5 fetal liver (A) and fetal spleen (G)
are depicted. Total MNCs of E17.5 FL (B) and spleen
(H), percentage of B-1 progenitor cells in FL (C) and
spleen (I), total cell number of B-1 progenitor cells in
FL (D) and spleen (J), percentage of AA4.1+CD19+
B220+ cells in FL (E) and spleen (K), and total cell
number of AA4.1+CD19+B220+ cells in FL (F) and
spleen (L) are shown. (B–F and H–L) Open bar, WT;
filled bar, Cbfβ−/−:Tek-GFP/Cbfβ. The cell numbers of
B-1 progenitors and CD19+B220+ cells from WT and
Cbfβ−/−:Tek-GFP/Cbfβ FL (M) and spleen (N) at each
embryonic day are shown (n = 4 for each group;
*<0.05, **<0.01).





















from WT and Cbfβ−/−:Tek-GFP/Cbfβ embryos into irradiated
NOD/SCID/IL2γc−/− (NSG) neonates. Although WT fetal-liver
MNCs displayed multilineage repopulation in the PB of the re-
cipient mice (Fig. 3A, Upper), no apparent engraftment was
found in the PB of the recipient mice transplanted with Cbfβ−/−:
Tek-GFP/Cbfβ fetal-liver MNCs as previously reported (16) (Fig.
3A, Lower). However, in the host peritoneal cavity and spleen,
B-1 and MZ B cells were reconstituted from donor Cbfβ−/−:Tek-
GFP/Cbfβ fetal-liver MNCs (Fig. 3B). No donor-derived B-2
cells or T cells were detected (Figs. 3B and 4E). These data in-
dicated that HSC-deficient fetal-liver MNCs contain progenitor
cells that can mature into only B-1 and MZ B cells in vivo
upon transplantation.
CBFβ Is Required for Maturation and Expansion of B-1 and MZ B Cells.
Although transplantable B-1 and MZ B-cell progenitors are
present in HSC-deficient fetal liver, the level of chimerism was
significantly lower than donor contributions from WT embryos
(WT 97.8 ± 1.3% vs. Cbfβ−/−:Tek-GFP/Cbfβ 1.98 ± 0.3% in the
peritoneal cavity and WT 92.8 ± 3.3% vs. Cbfβ−/−:Tek-GFP/Cbfβ
3.4 ± 2.4% in the spleen). It has been reported that Cbfβ is re-
quired in all blood-lineage cells for their development, but TEK-
GFP/Cbfβ expression was not sustained once Tek-GFP/Cbfβ+
HECs become hematopoietic cells (16, 17). We confirmed that
WT fetal-liver B-1 progenitor cells express Cbfβ at a similar level
to HSCs (Fig. 4A). However, B-1 progenitor cells from Cbfβ−/−:
Tek-GFP/Cbfβ do not express TEK-GFP/Cbfβ (Fig. 4B), thus
having lost Cbfβ expression during differentiation from TEK+
HEC to B-1 progenitor cells (Fig. 4C). We have also recently
determined that loss of Runx1 or Cbfβ in the B-cell lineage
caused B-2 cell maturation defects (31). In this mouse model of
Cbfβ deficient in B-cell lineage, we also observed a threefold
reduction in B-1 cell number compared with WT mice, indicating
that Cbfβ plays a critical role in B-1 cell development (Fig. S1)
(31). Thus, we hypothesized that Cbfβ−/−:Tek-GFP/Cbfβ fetal-
liver B-1 progenitor cells would require ongoing Cbfβ expression
to mature into functional B-1 cells. To test the hypothesis, we
overexpressed Cbfβ in Cbfβ−/−:Tek-GFP/Cbfβ fetal-liver MNCs
using a retrovirus vector that constitutively produced CBFβ (Fig.
4D and Fig. S2A). Once retrovirally infected fetal-liver Cbfβ−/−:
Tek-GFP/Cbfβ MNCs were transplanted into irradiated NSG
neonates, Cbfβ−/−:Tek-GFP/Cbfβ-derived cells displayed dramat-
ically improved engraftment capacity in up to 49% of donor cells
in the peritoneal cavity (Fig. 4E) and improved maturation into
IgM+ cells in the spleen (Fig. S3), and displayed only B-1 cell
reconstitution in the peritoneal cavity and MZ and B-1 cells in
the spleen 12 wk after transplantation (Fig. 4 E and F and Fig. S3).
Nearly all (98%) of these Cbfβ−/−:Tek-GFP/Cbfβ-derived cells
expressed retroviral Cbfβ-GFP (Fig. S2B) and displayed 15–25
times more Cbfβ mRNA expression compared with WT perito-
neal B-1 cells (Fig. S2C). In contrast, Cbfβ−/−:Tek-GFP/Cbfβ
fetal-liver cells infected with the empty vector control virus
poorly engrafted (Fig. 4E, Middle). These results indicate that
Cbfβ overexpression rescues maturation and expansion of im-
paired B-1 progenitor cells from Cbfβ−/−:Tek-GFP/Cbfβ em-
bryos. Furthermore, Cbfβ expressing engrafted B-1 cells in the
recipient mice were functional, displaying T cell-independent
antiphosphorylcholine IgM secretion detected by enzyme-linked
immunospot (Elispot) assay (Fig. 4 G and H). Taken together,
Cbfβ reexpression restored engraftment and expansion/mainte-
nance capacity of HSC-independent B-1 and MZ B cells from
Cbfβ−/−:Tek-GFP/Cbfβ fetal liver in vivo, suggesting that Cbfβ
plays important roles in B-1 cell development and proliferation,
similar to B-2 cell development (31). Of note, HSCs were not
restored by retrovirus Cbfβ overexpression in Cbfβ−/−:Tek-GFP/
Cbfβ fetal-liver cells: no engraftment of any hematopoietic lin-
eages other than B-1 or MZ B cells (Fig. 4E, Bottom, Fig. 4F, and
Fig. S3), suggesting that the timing and dose of Cbfβ expression
may be differentially required for the development of each
hematopoietic lineage.
Discussion
In the current study, using unique HSC-deficient embryos, we
have for the first time, to our knowledge, proven that progenitor
cells that give rise to only B-1 and MZ cells exist in the fetal liver
in the absence of HSCs. Although we were not able to quanti-
tatively estimate the percentage contribution of the first wave of
B cells in postnatal life (because the Cbfβ−/−:Tek-GFP/Cbfβ
neonates die just after birth), it is probable that at least 40% of
Fig. 2. (A) B-1 progenitor cells from Cbfβ−/−:Tek-GFP/Cbfβ fetal liver fail to
expand in vitro. AA4.1+CD19+B220lo-neg B-1 progenitor cells were sorted
from E17.5 WT and Cbfβ−/−:Tek-GFP/Cbfβ FL and plated on OP9 stromal
cells with IL-7 and Flt3-ligand. FACS dot plots of WT culture on day 10
(Upper) and Cbfβ−/−:Tek-GFP/Cbfβ culture on day 17 (Lower) are depicted.
Representative FACS dot plots from three separate experiments are
depicted. (B) YS and AGM cells from Cbfβ−/−:Tek-GFP/Cbfβ embryos can
produce B progenitor cells in vitro. E10 YS and AGM from WT (Upper) and
Cbfβ−/−:Tek-GFP/Cbfβ (Lower) embryos were plated on OP9 stromal cells
with IL-7 and Flt3-ligand. Cells after 10-d coculture were analyzed for their
surface markers by flow cytometry. Representative FACS dot plots from
two separate experiments (each experiment was done in triplicate) are
depicted.
Fig. 3. Cbfβ−/−:Tek-GFP/CBFβ fetal-liver cells contain a few B-1 and MZ
progenitor cells, but not HSCs. E15.5 FL MNCS from WT and Cbfβ−/−:Tek-GFP/
Cbfβ embryos were transplanted into sublethally irradiated NSG neonates.
PB analysis 8 wk after injection is depicted (A). PB of recipient mice trans-
planted with WT (Upper) and Cbfβ−/−:Tek-GFP/Cbfβ (Lower) fetal-liver cells
are depicted. (B) The peritoneal (Upper) and spleen (Lower) cells in the re-
cipient mice transplanted with Cbfβ−/−:Tek-GFP/Cbfβ fetal-liver cells are
shown. FO, follicular B cell.
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neonatal spleen B cells are derived from HSC-independent
progenitors. Since fetal-liver cells do not produce any blood cells
de novo but rely upon seeding from other sites, these B-1 pro-
genitor cells must have been seeded from another site(s) of
embryonic hematopoiesis, such as the yolk sac or embryo proper.
We also report that progenitor cells for MZ B cells developed
in the absence of HSCs in the Cbfβ−/−:Tek-GFP/Cbfβ embryos.
We previously identified YS/P-Sp–derived B-1 progenitor cells
as giving rise to MZ B cells upon transplantation in vivo (13).
The Cbfβ−/−:Tek-GFP/Cbfβ mouse model was instrumental in
again validating the HSC-independent origin of MZ B cells.
Because MZ B cells are also produced by adult BM HSCs and
splenic lin−CD19+B220lo-negCD43− precursors (7, 32), we spec-
ulate that MZ B cells may comprise precursors from heteroge-
nous sites. Ito et al. have reported less frequent generation of
MZ B than B-1 cells from YS lymphoid progenitors (33) but still
showed some MZ B-cell potential of the YS precursors. Dif-
ferences in their results from our present work may be the result
of differences in coculture lines and choice of cytokines or cy-
tokine concentrations. Ectopic expression of Lin28b has been
reported to reprogram adult hematopoietic stem/progenitor
cells into cells with the ability to give rise to fetal lymphopoiesis
(34). In this report, Lin28-expressing cells differentiated into
predominantly B-1a and MZ B cells in the recipient mice, in
agreement with our results. Thus, accumulating evidence sup-
ports a paradigm that a part of MZ B cells are derived from
embryonic precursors, similar to B-1 cells.
Another important finding from our current work is that Cbfβ
expression is required for B-1 cell development as well as B-2 cell
development as previously reported (31). However, B-1 cell
maturation is permissive in Cbfβ−/−:Tek-GFP/Cbfβ fetal liver-de-
rived B-1 progenitor cells, and the reduction of mature B-1a
cells in Cbfßflox/flox:MB1-cre mice is milder than the B-2 lineage.
Cbfβ may play different roles in the B-1 and the B-2 cell line-
ages, and further study would be required to fully explore the
roles played in each lineage.
In sum, the presence of transplantable B-1 and MZ progenitor
cells in the fetal liver devoid of HSCs confirms the first wave of B
lymphopoiesis in the immune layered model predicted more
than 20 y ago (1). Many questions remain to be addressed. How
do B-1 and MZ B-cell progenitors migrate into the fetal liver,
spleen, and BM? How and where do the B-1 progenitor cells
mature? How much do they really contribute to innate immunity
compared with fetal-liver HSC-derived B-1 and MZ B cells? Lin-
eage-tracing models would be required to resolve these questions,
and answering those questions would help to understand the roles
of B-1 cells in autoimmunity (35, 36), prevention of atherosclerosis
(37), and prevention of infections in blood stem cell transplanted
patients (38).
Materials and Methods
Mice. Cbfβ+/−: Tek-GFP/Cbfβ mice were generated by crossing Cbfβ+/− mice
and Tek-GFP/Cbfβ mice (kindly provided by Dr. Nancy Speck, University of
Pennsylvania, Philadelphia). To obtain Cbfβ−/−: Tek-GFP/Cbfβ embryos, timed
mating was performed by crossing Cbfβ+/−: Tek-GFP/Cbfβ males with Cbfβ+/−:
Tek-GFP/Cbfβ or Cbfβ+/− females. Embryonic tail was used for genotyping.
Transplantation. NSG neonates were used as recipients. One- to 5-d-old
neonates were sublethally irradiated (150 rad), and fetal-liver cells from WT
and Cbfβ−/−: Tek-GFP/Cbfβ embryos were injected into the peritoneal cavity
of NSG neonates. Six to 12 wk after injection, PB, peritoneal, and spleen cells
were analyzed donor cell types in the recipient mice.
OP9 Culture. An OP9 stromal cell line was maintained with α-MEM and 20%
(vol/vol) FBS. YS, P-Sp/AGM, or fetal-liver cells were plated on six-well plates
confluent with OP9 stromal cells in induction medium [α-MEM, 10% (vol/vol)
FBS and 5 × 10−5 M β-mercaptoethanol] supplemented with 10 ng/mL IL-7
and 10 ng/mL Flit3-ligand (PEPROTECH) as previously reported (13). Floating
cells in the culture medium were collected at optimal time points, and we
analyzed their surface markers by flow cytometry.
Flow Cytometry. For analysis and sorting of B-1 progenitors, B-1, MZ B Cells,
and each lineage of blood cells, the following antibodies were used at dif-
ferent fluorescent color combinations: anti-mouse AA4.1 (AA4.1), CD19
(1D3), B220 (RA3-6B2), IgM (II/41), CD21 (8D9), CD23 (B3B4), CD11b (M1/70),
Fig. 4. Overexpression of Cbfβ in Cbfβ−/−:Tek-GFP/Cbfβ fetal-liver cells re-
stored B-1 and MZ cell engraftment. (A) Cbfβ expression in WT fetal-liver
HSCs and B-1 progenitors by quantitative PCR is shown. Internal control:
β-actin = 1.0. (B) Tek-GFP/Cbfβ expression within E15.5 fetal-liver AA4.1+
CD19+B220dim B-1 progenitor cells in Cbfβ−/−:Tek-GFP/Cbfβ embryos. Red
line, WT; blue line, Cbfβ−/−:Tek-GFP/Cbfβ fetal-liver B-1 progenitor cells. (C)
Relative Cbfβ expression in E9.5 WT CD31+Tie2+ HECs, E9.5 Cbfβ−/−:Tek-GFP/
Cbfβ HECs, E14.5 WT FL B-1progenitors, and E14.5 Cbfβ−/−:Tek-GFP/Cbfβ FL
B-1 progenitors, compared with E9.5 WT HECs (=1). Open bar, WT; filled bar,
Cbfβ−/−:Tek-GFP/Cbfβ. (D) Experimental design for rescuing Cbfβ expression
in Cbfβ−/−:Tek-GFP/Cbfβ fetal-liver cells. (E) Peritoneal cells of recipient mice
at 12 wk after transplantation with fetal-liver cells from WT (Top) or Cbfβ−/−:
Tek-GFP/Cbfβ fetal-liver cells expressing empty vector (Middle) or Cbfβ
(Bottom), respectively. (F) Donor-derived B-cell subsets in the recipient
peritoneal cavity (Left) and spleen (Right) are depicted. Donor cells were WT
fetal-liver MNC cells (left bars), Cbfβ−/−:Tek-GFP/Cbfβ fetal-liver cells (center
bars), and Cbfβ−/−:Tek-GFP/Cbfβ fetal-liver cells infected with Cbfβ expressing
retrovirus (rescue, right bars), in each panel. (G) IgM secretions from B-1 or B-
2 cells stimulated with phosphorylcholine were detected by Elispot assay: (a)
1,000 B-1 cells from the recipient mice transplanted with WT fetal-liver cells
with empty vector, (b) 650 B-1 cells derived from Cbfβ−/−:Tek-GFP/Cbfβ fetal-
liver cells with Cbfβ expression vector, and (c) 1,000 B-2 cells derived fromWT
fetal-liver cells with empty vector were initially plated. (H) The numbers of
spots per 1,000 B-1 or B-2 cells derived from recipient mice in Elispot assay (G,
a, b, and c) are depicted. There was no significant difference between B-1
cells from WT fetal liver with empty vector and from Cbfβ−/−:Tek-GFP/Cbfβ
fetal liver with Cbfβ expression vector. The number of IgM-secreting B-2 cells
was significantly less than that of B-1 cells from WT or Cbfβ−/−:Tek-GFP/Cbfβ
with Cbfβ expression vector (<0.05).





















CD5 (53-7.3), CD3e (145-2C11), Ter119 (TER-119), c-kit (2B8), Sca-1 (D7), and IL-
7Ra (A7R34) (all purchased from eBioscience). A lineage mixture containing
anti-Ter119, CD11b, and CD3was used for lineage negative gating. Cells were
analyzed on LSRII or sorted on FACS Aria (Becton Dickinson).
Quantitative PCR. Fetal-liver Lin−Sca-1+c-kit+ cells or AA4.1+CD19+B220lo-neg
B-1 progenitors were sorted, and RNA was extracted using RNasy (QIAGEN)
following the manufacturer’s instructions. cDNA was made using Super Scrip
III fast strand Synthesis System (Invitrogen). Real-time PCR was performed
using FastStart Universal SYBR Green Master (Rox) (Roche) by 7500 Real-
Time PCR System (Life Technologies). The following sets of primers were
used: Cbfβ, forward, GCAAGTTCGAGAACGAGGAG; reverse, CCCGTGTACT-
TAATCTCGCA; β-actin, forward, TCCTGTGGCATCCATGAAACT; reverse, GAAG-
CACTTGCGGTGCACGAT.
Expression Vectors and Retrovirus Production. Full-length cDNA of mouse Cbfβ
was purchased from TrueClone (catalog no. MC204426) and amplified by
PCR. cDNA of mouse Cbfβ was inserted into an MSCV-IRES-GFP (MIG) plas-
mid. Retroviruses carrying empty vector (MIG-empty) or MIG-Cbfβ were
produced using the Phoenix cell line. Virus supernatants were concentrated
by centrifuging at 19,000 × g, 4 °C for 100 min. WT and Cbfβ−/−: Tek-GFP/
Cbfβ fetal-liver MNCs were plated on retronectin-coated 24-well plates in
inductionmedium with 10 ng/mL stem cell factor, 10 ng/mL IL-7, and 10 ng/mL
Flit3-ligand. Concentrated virus supernatant was added into each well, and
spin infection was performed by centrifuging at 1,000 × g, 32 °C for 100 min.
The next morning, the medium was half changed, and second-spin infection
was done. Three hours after second infection, cells were harvested and used
for the transplantation assay. Infectious efficiency was confirmed by detecting
GFP+ cells by flow cytometry.
Elispot. Elispot was done as previously described (39). Donor-derived B-1 or
B-2 cells in the peritoneal cavity of recipient mice were sorted on a FACS Aria
(Becton Dickinson), suspended in Elispot medium (RPMI 1640 medium with
10% FBS and 5 × 10−5 M β-mercaptoethanol), supplemented with 10 ng/mL
IL-5, and cultured for 36–48 h in 96-well plates precoated with phosphor-
ylcholine-conjugated keyhole limpet hemocyanin. Five hundred to 1,000
cells were distributed into an Elispot MultiScreenHTS Filter Plate (Millipore)
precoated with anti-mouse IgM and cultured in Elispot medium over-
night. After washing, alkaline phosphatase-conjugated goat anti-mouse
IgM (Southern Biotech) was applied to each well and incubated for 45
min. After washing, spots were visualized using BCIP/NBTplus substrate
as described (Mabtech).
Statistics. All experiments were completed in triplicate. The Student t test
was used for statistical analysis.
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